Search Visibility Audit

Current

18S Amplicon Sequencing for Cancer-Associated Parasite Detection The PathOID.ai Cancer ID Screen uses 18S ribosomal RNA amplicon sequencing across multiple sample types to identify parasitic organisms with known or emerging associations to human malignancy. Certain parasites have been classified as Group 1 carcinogens by the International Agency for Research on Cancer (IARC). Others are under active investigation for their roles in chronic inflammation, immune suppression, and oncogenic transformation. This screen surveys your samples for the presence of these organisms at the genetic level. Accepted Sample Types: Stool, urine, cheek swab, hair follicle, blood, cerebrospinal fluid (CSF), and tissue What this screen looks for: Parasitic DNA signatures associated with colorectal, bladder, bile duct, and brain cancers Organisms such as Schistosoma , Opisthorchis , Toxoplasma , Blastocystis , and related eukaryotes Eukaryotic microbial patterns across multiple tissue compartments simultaneously Future applications of this screen may expand into dedicated clinical and research tissue sequencing pipelines under a specialized oncology-focused platform. ⚠️ This is not a diagnostic test. The PathOID.ai Cancer ID Screen is an investigational educational tool built for awareness and research purposes only. It does not diagnose, treat, or rule out cancer or any parasitic infection. Results are for educational use only. Always consult a qualified physician regarding any health concerns.